Eli Lilly announced its oral obesity drug Foundayo captured over 30% of new US patients, narrowing the gap with rival Novo Nordisk. Market analysts expect the obesity treatment sector to reach over $1
Britain's MHRA approved Eli Lilly's oral weight-loss pill Foundayo for diabetes and weight management, marking the first European authorization. The drug launches privately later this month, intensify
Asian stocks declined as AI momentum faded, influenced by geopolitical hopes easing oil prices. Eli Lilly raised sales guidance on weight-loss drugs, contrasting with broader market caution.
Eli Lilly raised its full-year revenue forecast following better-than-expected quarterly results driven by GLP-1 drug sales Mounjaro and Zepbound. Shares surged 5% amid resilient demand despite pricin
Eli Lilly and Resilience plan to invest $750 million to expand U.S. pharmaceutical manufacturing capacity, strengthening the domestic medicine supply chain and creating 400 jobs. The partnership will
Novo Nordisk sued Eli Lilly in U.S. court, alleging false advertising claims comparing their weight-loss drugs Zepbound and Wegovy. The lawsuit underscores fierce competition in the obesity market, re
US premarket trading saw mixed results amid geopolitical tensions and corporate earnings. Notable movements included an oil tanker strike impacting energy sectors and Eli Lilly exploring an acquisitio
Novo Nordisk and Eli Lilly’s GLP-1 weight-loss drugs are transforming consumer spending, boosting apparel sales while causing sharp declines in plus-size retail. Market analysts predict significant sh
Eli Lilly transferred mainland China commercialization rights for its breast cancer drug Verzenios to Innovent Biologics due to generic competition. Lilly will continue manufacturing and supplying the
Eli Lilly solidified its obesity drug market leadership after presenting superior trial data at the American Diabetes Association meeting. Competitors like Roche and Pfizer unveiled new candidates, th
Novo Nordisk and Eli Lilly see patients switching to lower-priced oral weight-loss pills over compounded versions, expanding market access despite ongoing insurance coverage challenges.
Eli Lilly's new oral weight-loss drug Foundayo recorded 7,335 prescriptions in its fourth week, trailing rival Wegovy but showing early traction. Analysts suggest investors are looking past initial me
US stock futures rose on tech earnings and economic data, with oil prices retreating from peaks and Japan intervening in forex markets. Eli Lilly raised forecasts on soaring obesity medication demand,
U.S. stock indices are on track for their best monthly performance since 2020, supported by strong earnings despite oil price spikes from Middle East tensions. Eli Lilly and Caterpillar led gains, whi
Eli Lilly's new oral obesity drug Foundayo recorded 3,707 U.S. prescriptions in its second week, falling short of analyst expectations compared to competitor Novo Nordisk's Wegovy. Shares dropped near
Eli Lilly is reportedly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, per the Wall Street Journal. Reuters noted it could not immediately verify the report.
Eli Lilly's obesity pill Foundayo recorded 1,390 U.S. prescriptions in its debut week, trailing Novo Nordisk's oral Wegovy. Launch data underscores intensifying competition in the oral obesity drug ma
Business watch notes plant closures in Brazil and the UK plus Eli Lilly's $1.2B Ventyx acquisition. Geopolitical unrest in Venezuela and Iran threatens global oil and petrochemical supply chains.
ChemBrief